FRTX vs. MTEX, NXTC, INAB, LSTA, TNXP, SNTI, LIAN, MRKR, CARM, and GELS
Should you be buying Fresh Tracks Therapeutics stock or one of its competitors? The main competitors of Fresh Tracks Therapeutics include Mannatech (MTEX), NextCure (NXTC), IN8bio (INAB), Lisata Therapeutics (LSTA), Tonix Pharmaceuticals (TNXP), Senti Biosciences (SNTI), LianBio (LIAN), Marker Therapeutics (MRKR), Carisma Therapeutics (CARM), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry.
Fresh Tracks Therapeutics vs.
Fresh Tracks Therapeutics (NASDAQ:FRTX) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.
Mannatech received 318 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 77.00% of users gave Mannatech an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote.
Fresh Tracks Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
Fresh Tracks Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -1.26%. Fresh Tracks Therapeutics' return on equity of 0.00% beat Mannatech's return on equity.
In the previous week, Fresh Tracks Therapeutics and Fresh Tracks Therapeutics both had 1 articles in the media. Fresh Tracks Therapeutics' average media sentiment score of 0.71 beat Mannatech's score of 0.00 indicating that Fresh Tracks Therapeutics is being referred to more favorably in the media.
25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Mannatech has higher revenue and earnings than Fresh Tracks Therapeutics. Mannatech is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Fresh Tracks Therapeutics and Mannatech tied by winning 7 of the 14 factors compared between the two stocks.
Get Fresh Tracks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresh Tracks Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FRTX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free FRTX Stock Alerts